Research programme: fibrotic liver diseases therapeutics - Boehringer Ingelheim/MiNA Therapeutics

Drug Profile

Research programme: fibrotic liver diseases therapeutics - Boehringer Ingelheim/MiNA Therapeutics

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; MiNA Therapeutics
  • Class
  • Mechanism of Action RNA interference; RNA stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Non-alcoholic steatohepatitis

Most Recent Events

  • 14 Nov 2017 MiNA Therapeutics has patent protection for saRNA technology platform in USA granted before November 2017 (MiNA Therapeutics pipeline, November 2017)
  • 09 Nov 2017 Boehringer Ingelheim and MiNA Therapeutics enter into a collaboration agreement to develop fibrotic liver diseases therapeutics
  • 09 Nov 2017 Early research in Non-alcoholic steatohepatitis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top